Pyrogallol inhibits T cell lymphoma growth by mediating G2/M phase cell cycle arrest, apoptosis, glycolysis and immune evasion: an implication of AKT pathway.
A plant compound stops T-cell lymphoma growth in early testing through cell cycle arrest and immune modulation pathways.
Pyrogallol suppresses T-cell lymphoma growth in preclinical models via G2/M cell cycle arrest, apoptosis induction, glycolysis inhibition, and immune evasion modulation through AKT pathway inhibition. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- preclinical_experimental
- Category
- hematologic_malignancies
- Maturity
- Exploratory
- Journal
- Cytotechnology
Why it surfaced
Preclinical natural compound anti-T-cell lymphoma activity; low translational immediacy but mechanistically relevant to AKT pathway targeting in lymphoma.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.